Penciclovir
Side effects
Options: Show MedDRA Preferred Terms
| Side effect | Data for drug | Placebo | Labels | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | |||
| Headache | postmarketing, 8.5% - 39.3% | 5.4% - 42.9% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x |
| Diarrhoea | 1.6% - 9% | 0.8% - 9.5% | x | x | x | x | x | x | x | x | x | x | ||||||
| Neutropenia | 3.2% | 1.5% | x | x | x | x | x | x | x | x | x | x | ||||||
| Nausea | 2.2% - 12.5% | 3.6% - 11.6% | x | x | x | x | x | x | x | x | x | x | ||||||
| Dysmenorrhoea | 0% - 7.6% | 0% - 6.3% | x | x | x | x | x | x | x | x | x | x | ||||||
| Fatigue | 0.6% - 4.8% | 0% - 3.4% | x | x | x | x | x | x | x | x | x | x | ||||||
| Leukopenia | 1.3% | 0.9% | x | x | x | x | x | x | x | x | x | x | ||||||
| Vomiting | 0.7% - 4.8% | 0% - 3.4% | x | x | x | x | x | x | x | x | x | x | ||||||
| Hypoaesthesia | 0.9% | 1.4% | x | x | x | x | x | |||||||||||
| Application site reaction | postmarketing, 1.3% | 1.8% | x | x | ||||||||||||||
| Flatulence | 0.2% - 4.8% | 0% - 1.6% | x | x | x | x | x | x | x | x | x | x | ||||||
| Migraine | 0.2% - 3.1% | 0% - 0.7% | x | x | x | x | x | x | x | x | x | x | ||||||
| Abdominal pain | 0% - 7.9% | 0.4% - 7.9% | x | x | x | x | x | x | x | x | x | x | ||||||
| Dysgeusia | 0.2% | 0.3% | x | x | x | x | ||||||||||||
| Anaemia | 0.1% | 0% | x | x | x | x | x | x | x | x | x | x | ||||||
| Angioedema | postmarketing | x | x | x | x | x | x | x | x | x | ||||||||
| Mental disorder | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Confusional state | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Delirium | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Dizziness | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Toxic epidermal necrolysis | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Erythema multiforme | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Hallucination | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Cardiac disorder | postmarketing | x | x | x | x | x | x | |||||||||||
| Herpes labialis | postmarketing | x | x | x | x | |||||||||||||
| Jaundice cholestatic | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Nervous system disorder | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Pain | postmarketing, 0% | 0.1% | x | x | x | x | x | x | ||||||||||
| Palpitations | postmarketing | x | x | x | x | x | x | |||||||||||
| Paraesthesia | postmarketing, 0% - 2.6% | 0% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x |
| Pruritus | postmarketing, 0% - 3.7% | 0% - 2.7% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x |
| Stevens-Johnson syndrome | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Thrombocytopenia | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Urticaria | postmarketing | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |
| Liver function test abnormal | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Skin discolouration | postmarketing | x | x | x | x | x | x | |||||||||||
| Unspecified disorder of skin and subcutaneous tissue | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Disorientation | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Rash erythematous | postmarketing | x | x | x | x | |||||||||||||
| Therapeutic response decreased | postmarketing | x | x | x | x | x | x | |||||||||||
| Pharyngeal oedema | postmarketing | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |
| Hepatobiliary disease | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Blood and lymphatic system disorders | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Local swelling | postmarketing | x | x | x | x | x | x | |||||||||||
| Parosmia | postmarketing | x | x | x | x | x | x | |||||||||||
| Somnolence | postmarketing | x | x | x | x | x | x | x | x | x | x | |||||||
| Leukocytoclastic vasculitis | postmarketing | x | x | x | x | x | x | |||||||||||
| Rash | 0% - 3.3% | 0% - 1.6% | x | x | x | x | x | x | x | x | x | x | x | x | x | x | ||
| Hypersensitivity | 0% | 0.1% | x | x | x | |||||||||||||
| Renal failure acute | x | x | x | x | x | x | x | x | x | x | ||||||||
| Erythema | x | x | x | x | x | x | ||||||||||||
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Color scheme:
standard – alternative
| 100% | ||
| 75% | ||
| 50% | ||
| 10% | ||
| frequent (1% to 100%) | ||
| infrequent (0.1% to 1%) | ||
| rare (<0.1%) | ||
| postmarketing | ||
| 0% | ||
| no frequency information | ||
| not found on label |
